About: Opiranserin

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Opiranserin (INN; developmental code name VVZ-149) is a selective and combined glycine GlyT2 transporter blocker (IC50 = 0.86 μM), purine P2X3 receptor antagonist (IC50 = 0.87 μM), and serotonin 5-HT2A receptor antagonist (IC50 = 1.3 μM) which is under development by Vivozon for the intravenous treatment of postoperative pain. As of April 2017, it is in phase II clinical trials for this indication. The INN of the drug was issued in 2017.

Property	Value
dbo:abstract	Opiranserin (INN; developmental code name VVZ-149) is a selective and combined glycine GlyT2 transporter blocker (IC50 = 0.86 μM), purine P2X3 receptor antagonist (IC50 = 0.87 μM), and serotonin 5-HT2A receptor antagonist (IC50 = 1.3 μM) which is under development by Vivozon for the intravenous treatment of postoperative pain. As of April 2017, it is in phase II clinical trials for this indication. The INN of the drug was issued in 2017. (en)
dbo:casNumber	1441000-45-8
dbo:fdaUniiCode	AP031EC2NI
dbo:pubchem	71566778
dbo:thumbnail	wiki-commons:Special:FilePath/Opiranserin.svg?width=300
dbo:wikiPageID	55146737 (xsd:integer)
dbo:wikiPageLength	4156 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1082622930 (xsd:integer)
dbo:wikiPageWikiLink	dbc:Receptor_antagonists dbr:Intravenous_therapy dbc:Analgesics dbc:Dimethylamino_compounds dbc:Experimental_drugs dbr:Glycine dbr:Clinical_trial dbr:Receptor_antagonist dbr:5-HT2A_receptor dbc:5-HT2A_antagonists dbc:Benzamides dbr:Glycine_reuptake_inhibitor dbr:Glycine_transporter dbc:Glycine_reuptake_inhibitors dbr:Binding_selectivity dbr:Glycine_transporter_2 dbr:Phases_of_clinical_research dbr:P2X3 dbr:Serotonin_receptor dbr:Purine_receptor dbr:Postoperative_pain
dbp:c	21 (xsd:integer)
dbp:casNumber	1441000 (xsd:integer)
dbp:h	34 (xsd:integer)
dbp:iupacName	4 (xsd:integer)
dbp:n	2 (xsd:integer)
dbp:o	5 (xsd:integer)
dbp:pubchem	71566778 (xsd:integer)
dbp:routesOfAdministration	dbr:Intravenous_therapy
dbp:smiles	O=CC2=CC=CC=C2 (en)
dbp:stdinchi	1 (xsd:integer)
dbp:stdinchikey	JQUVQWMHZSYCRQ-UHFFFAOYSA-N (en)
dbp:synonyms	VVZ-149; VVZ-000149 (en)
dbp:unii	AP031EC2NI (en)
dbp:width	250 (xsd:integer)
dbp:wikiPageUsesTemplate	dbt:Purine_receptor_modulators dbt:Abbr dbt:Drugbox dbt:Glycine_receptor_modulators dbt:Reflist dbt:Serotonin_receptor_modulators dbt:Short_description dbt:Abbrlink dbt:Fdacite
dct:subject	dbc:Receptor_antagonists dbc:Analgesics dbc:Dimethylamino_compounds dbc:Experimental_drugs dbc:5-HT2A_antagonists dbc:Benzamides dbc:Glycine_reuptake_inhibitors
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug
rdfs:comment	Opiranserin (INN; developmental code name VVZ-149) is a selective and combined glycine GlyT2 transporter blocker (IC50 = 0.86 μM), purine P2X3 receptor antagonist (IC50 = 0.87 μM), and serotonin 5-HT2A receptor antagonist (IC50 = 1.3 μM) which is under development by Vivozon for the intravenous treatment of postoperative pain. As of April 2017, it is in phase II clinical trials for this indication. The INN of the drug was issued in 2017. (en)
rdfs:label	Opiranserin (en)
owl:sameAs	wikidata:Opiranserin https://global.dbpedia.org/id/3cPt8
prov:wasDerivedFrom	wikipedia-en:Opiranserin?oldid=1082622930&ns=0
foaf:depiction	wiki-commons:Special:FilePath/Opiranserin.svg
foaf:isPrimaryTopicOf	wikipedia-en:Opiranserin
is dbo:wikiPageRedirects of	dbr:C21H34N2O5 dbr:VVZ-000149 dbr:VVZ-149 dbr:VVZ000149 dbr:VVZ149 dbr:VVZ_000149 dbr:VVZ_149
is dbo:wikiPageWikiLink of	dbr:C21H34N2O5 dbr:Sodium-_and_chloride-dependent_glycine_transporter_2 dbr:P2RX3 dbr:VVZ-000149 dbr:VVZ-149 dbr:VVZ000149 dbr:VVZ149 dbr:VVZ_000149 dbr:VVZ_149
is foaf:primaryTopic of	wikipedia-en:Opiranserin